The abstract is read at the publisher; the summary is JClub's.
A microbiological review synthesizes evidence on newly approved and investigational β-lactams and β-lactam/β-lactamase inhibitor combinations designed to restore activity against carbapenemase-producing Enterobacterales.
- Why it matters: Carbapenemase-producing Enterobacterales spread globally and carbapenem activity is severely compromised by diverse Ambler classes A, B, and D enzymes, threatening treatment of severe multidrug-resistant Gram-negative infections.
- What they did: The review surveys structural and mechanistic features of key agents, including cefiderocol and multiple β-lactam/β-lactamase inhibitor combinations, emphasizing inhibitor spectra and antimicrobial activity tested against isogenic strains and large collections of clinical Enterobacterales isolates.
- The result: It highlights emerging resistance mechanisms that may compromise clinical effectiveness, supporting mechanistic understanding to guide therapeutic positioning and inform next-generation antimicrobial development against CRE.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.